210 related articles for article (PubMed ID: 34907331)
21. Lung cancer in 2016: immunotherapy comes of age.
Mitchell PL; John T
Lancet Respir Med; 2016 Dec; 4(12):947-949. PubMed ID: 27890503
[No Abstract] [Full Text] [Related]
22. Development and clinical application of bispecific antibody in the treatment of colorectal cancer.
Balibegloo M; Rezaei N
Expert Rev Clin Immunol; 2020 Jul; 16(7):689-709. PubMed ID: 32536227
[TBL] [Abstract][Full Text] [Related]
23. An update on the use of immunotherapy in patients with colorectal cancer.
Nguyen M; Tipping Smith S; Lam M; Liow E; Davies A; Prenen H; Segelov E
Expert Rev Gastroenterol Hepatol; 2021 Mar; 15(3):291-304. PubMed ID: 33138649
[No Abstract] [Full Text] [Related]
24. Clinical efficacy and safety of nimotuzumab plus chemotherapy in patients with advanced colorectal cancer: a retrospective analysis.
Bai SX; Zhang RR; Chen WH; Dong HM; Wang G; Li XK; Wang W
J Int Med Res; 2020 Jan; 48(1):300060519895858. PubMed ID: 31948326
[TBL] [Abstract][Full Text] [Related]
25. An update on colorectal cancer microenvironment, epigenetic and immunotherapy.
Jin K; Ren C; Liu Y; Lan H; Wang Z
Int Immunopharmacol; 2020 Dec; 89(Pt A):107041. PubMed ID: 33045561
[TBL] [Abstract][Full Text] [Related]
26. MMR deficiency may lead to a high immunogenicity and then an improvement in anti-PD-1 efficacy for metastatic colorectal cancer.
Aguiar PN; Tadokoro H; Forones NM; de Mello RA
Immunotherapy; 2015; 7(11):1133-4. PubMed ID: 26568256
[No Abstract] [Full Text] [Related]
27. Two Months of Therapy: A Case of Pathologic Complete Response to Chemoimmunotherapy in a Patient With Metastatic Colorectal Cancer.
Armstrong S; Al-Ghawi H; Helft P; House MG; Spittler AJ; Wu HH; Shahda S
Clin Colorectal Cancer; 2018 Jun; 17(2):e229-e232. PubMed ID: 29311032
[No Abstract] [Full Text] [Related]
28. Single-Agent Immunotherapy for Two Types of Cancer in One Patient.
Musher B; Rahal A
Ann Intern Med; 2019 Feb; 170(3):210-211. PubMed ID: 30264147
[No Abstract] [Full Text] [Related]
29. Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management.
Overman MJ; Ernstoff MS; Morse MA
Am Soc Clin Oncol Educ Book; 2018 May; 38():239-247. PubMed ID: 30231358
[TBL] [Abstract][Full Text] [Related]
30. Novel avenues in immunotherapies for colorectal cancer.
Pardieck IN; Jawahier PA; Swets M; van de Velde CJ; Kuppen PJ
Expert Rev Gastroenterol Hepatol; 2016; 10(4):465-80. PubMed ID: 26582071
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy in gastroesophageal cancers: Current state and future directions.
Shaikh H; Kamran A; Monga DK
J Oncol Pharm Pract; 2021 Mar; 27(2):395-404. PubMed ID: 33050805
[TBL] [Abstract][Full Text] [Related]
32. Durable complete response to pembrolizumab in microsatellite stable colorectal cancer.
Gomar M; Najafi M; Aghili M; Cozzi S; Jahanbakhshi A
Daru; 2021 Dec; 29(2):501-506. PubMed ID: 34254265
[TBL] [Abstract][Full Text] [Related]
33. [Pembrolizumab as first-line therapy in microsatellite instability metastatic colorectal cancers].
Pureur D; Rodrigues M; Turpin A
Bull Cancer; 2021 Mar; 108(3):229-231. PubMed ID: 33632546
[No Abstract] [Full Text] [Related]
34. Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab.
Das S; Allen A; Berlin J
Clin Colorectal Cancer; 2020 Jun; 19(2):137-140. PubMed ID: 32146081
[TBL] [Abstract][Full Text] [Related]
35. A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer.
Grothey A; Strosberg JR; Renfro LA; Hurwitz HI; Marshall JL; Safran H; Guarino MJ; Kim GP; Hecht JR; Weil SC; Heyburn J; Wang W; Schweizer C; O'Shannessy DJ; Diaz LA
Clin Cancer Res; 2018 Jan; 24(2):316-325. PubMed ID: 29084918
[No Abstract] [Full Text] [Related]
36. Efficacy and clinical monitoring strategies for immune checkpoint inhibitors and targeted cytokine immunotherapy for locally advanced and metastatic colorectal cancer.
Bess SN; Greening GJ; Muldoon TJ
Cytokine Growth Factor Rev; 2019 Oct; 49():1-9. PubMed ID: 31679887
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches.
Tintelnot J; Stein A
World J Gastroenterol; 2019 Aug; 25(29):3920-3928. PubMed ID: 31413527
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden.
Gong J; Robertson MD; Kim E; Fakih M; Schrock AB; Tam KW; Burugapalli B; Monjazeb AM; Hendifar AE; Hitchins M; Klempner SJ; Cho M
Clin Colorectal Cancer; 2019 Dec; 18(4):307-309. PubMed ID: 31563511
[No Abstract] [Full Text] [Related]
39. The promise and challenges of neoadjuvant immunotherapy in the management of non-metastatic muscle-invasive bladder cancer.
Janisch F; Rink M; Shariat SF
BJU Int; 2020 Jun; 125(6):753-755. PubMed ID: 32011069
[No Abstract] [Full Text] [Related]
40. Results and challenges of immune checkpoint inhibitors in colorectal cancer.
Emambux S; Tachon G; Junca A; Tougeron D
Expert Opin Biol Ther; 2018 May; 18(5):561-573. PubMed ID: 29471676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
